Figma Shares Indicated To Open $105/$110
In a turbulent market environment, Allovir Inc (KLRS) stock has been under significant pressure, touching a 52-week low of $3.09. According to InvestingPro data, the stock’s RSI indicates oversold territory, while the company maintains a strong current ratio of 14.31 and holds more cash than debt. The biopharmaceutical company, which focuses on developing treatments for viral diseases, has seen its shares plummet over the past year, reflecting a stark 1-year change with a decline of -82.52%. Investors have been cautious as the company navigates through a challenging phase, marked by this notable drop in its stock price from previous levels. The current 52-week low serves as a critical point for Allovir, as market watchers and stakeholders closely monitor the company’s performance and potential recovery strategies. With a market capitalization of $58.54 million and analyst price targets ranging from $20-21, InvestingPro analysis suggests the stock may be undervalued at current levels. Discover 8 additional key insights about KLRS with an InvestingPro subscription.
In other recent news, Kalaris Therapeutics announced new executive compensation arrangements, including a revised employment agreement for CEO Andrew Oxtoby, effective April 2025. This agreement includes a base salary of $569,100 and a potential annual performance bonus up to 55% of his salary, contingent on the Board’s assessment. The company also amended the offer letter for Brett Hagen, Senior Vice President and Chief Accounting Officer, to include severance benefits. Additionally, Kalaris appointed Leone Patterson to its Board of Directors, where she will serve as Chair of the Audit Committee. Patterson’s extensive experience in biotech finance and operations is expected to enhance the company’s governance.
In analyst updates, Leerink Partners initiated coverage on Kalaris with an Outperform rating and a $20 price target, citing the significant market opportunity for its investigational therapy, TH103, in treating wet age-related macular degeneration. William Blair also began coverage with an Outperform rating and a $21 fair value estimate, highlighting the potential market for Kalaris’ retinal vascular disease treatments. These ratings reflect confidence in the company’s prospects and its ability to address unmet needs in the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.